Tandem Diabetes shares climb 5% after Stifel upgrades stock to Buy
Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) climbed 5.1% in premarket trading after Stifel upgraded the medical device maker to Buy from Hold. The upgrade cites an improving margin trajectory, upcoming product catalysts like the tubeless Mobi system, and the company's transition into the pharmacy channel, which is expected to support recurring revenue growth. Stifel also raised its price target on the stock to $26.00 from $22.00, anticipating strengthened operational efficiency and adjusted EBITDA margins reaching the low teens by 2028.
Tandem Diabetes Care upgraded by Stifel with a new price target
Stifel has upgraded Tandem Diabetes Care (TNDM) from Hold to Buy, setting a new price target of $26.00. This upgrade comes after recent positive news for Tandem, including FDA clearance for its Mobi insulin pump and multiple Health Canada approvals for its t:slim X2 Insulin Pump. Historically, TNDM has shown positive movement after analyst upgrades, closing higher in the next session six out of six times since December 2025.
Form 4 Tandem Diabetes Care Inc: Elizabeth Anne Gasser (EVP, Chief Strategy Officer) For: 15 November
This article reports on a Form 4 filing for Tandem Diabetes Care Inc., detailing an insider transaction involving Elizabeth Anne Gasser, the EVP and Chief Strategy Officer. The transaction date is specified as November 15, though no further details about the nature of the transaction are provided in the snippet.
535 shares withheld for taxes at Tandem Diabetes Care (TNDM); no shares were sold.
Tandem Diabetes Care's EVP & Chief Operating Officer, Kyrillos Jean-Claude, acquired 207 common shares through an Employee Stock Purchase Plan on November 16, 2026. Additionally, on November 15, 2026, 1,009 restricted stock units converted into common stock, with 535 common shares withheld for tax purposes at $20.07 per share. The report explicitly states that no shares were sold.
MiniMed gets FDA nod for tubeless insulin pump
MiniMed has received FDA clearance for its first tubeless insulin pump, the MiniMed Fit, designed for individuals with Type 1 and Type 2 diabetes aged seven and older. The device can be worn for up to seven days, holds 300 units of insulin, and features a meal detection algorithm. MiniMed aims to compete with Insulet and Tandem Diabetes Care in the patch pump market, with a phased U.S. rollout planned for spring 2027.
Five filers report the same 3.62M-share stake in Tandem Diabetes Care (TNDM).
Five reporting persons, including Balyasny Asset Management L.P. and Dmitry Balyasny, have each disclosed a beneficial ownership of 3,624,727 common shares, representing approximately 5.21% of Tandem Diabetes Care (TNDM). These shares are directly held by Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P. The filing is a Schedule 13G, indicating a passive investment, and the reported percentage is based on 69,578,707 shares outstanding as of August 3, 2026.
FDA clears Tandem Diabetes insulin pump for tubeless insulin delivery
Tandem Diabetes Care has received FDA clearance for its Tandem Mobi insulin pump to be used as a tubeless automated insulin delivery system, offering both tubed and tubeless options with the same device. The new tubeless cartridge and infusion set can be used for up to seven days and are compatible with existing Tandem Mobi pumps. This expansion allows more people with diabetes to benefit from the company's Control-IQ+ AID technology, with a launch expected in the first half of 2027.
Tandem Mobi sees FDA clearance for tubeless AID system
Tandem Diabetes Care has received FDA clearance for its Tandem Mobi system, a tubeless automated insulin delivery device approved for up to seven days of wear. This new system offers users the flexibility to choose between tubeless and tubed insulin infusion options, making it unique in the market. The company plans a U.S. commercial launch in 2027, with tubeless infusion sets and cartridges available via pharmacy benefits.
Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
Tandem Diabetes Care has received FDA clearance for a tubeless version of its miniaturized Mobi automated insulin delivery system, allowing it to be worn on the skin for up to seven days. This new cartridge and infusion set will be launched commercially in the first half of next year through pharmacy channels, providing an extended wear time compared to competitors. The Mobi pump, initially launched in 2024, was designed to be compatible with different wear options, meaning existing users will only need the new accessories.
Tandem Diabetes Care, Inc. (TNDM) stock price, news, quote and history
Tandem Diabetes Care, Inc. (TNDM) is a medical device company specializing in technology solutions for people with diabetes, including insulin delivery systems like the t:slim X2 and Tandem Mobi pumps. The article provides a comprehensive overview of TNDM's stock performance, key financial metrics, recent news, and analyst insights. As of November 16, the stock closed at $18.48, experiencing a decline, while analysts have an average target price of $26.90.
Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
Tandem Diabetes Care (NASDAQ:TNDM) has received FDA clearance for its Tandem Mobi insulin pump to offer both tubed and tubeless wear options, making it the first and only system of its kind. The new tubeless cartridge and infusion set will convert existing Mobi pumps and are designed to simplify diabetes management with less frequent site changes, integrating with Control-IQ+ technology. Tandem plans a commercial launch in the U.S. in the first half of 2027, with products exclusively available through pharmacies.
Tandem Diabetes Care Receives FDA Clearance for Tandem Mobi
Tandem Diabetes Care announced that it received FDA 510(k) clearance for Tandem Mobi, described as the world's first and only tubeless automated insulin delivery system offering up to 7 days of wear. This system provides users with both tubed and tubeless infusion options, simplifying diabetes management with less frequent site changes and integrating Control-IQ+ advanced hybrid closed-loop technology. While analysts have given TNDM a Buy rating with a $40.00 price target, TipRanks' AI Analyst, Spark, rates TNDM as Neutral due to weaker financial quality despite improving margins.
Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear
Tandem Diabetes Care announced FDA clearance for Tandem Mobi as the world's first and only tubeless automated insulin delivery (AID) system with up to seven days of wear. This innovation, featuring a new tubeless cartridge and infusion set, allows the existing Tandem Mobi pump to be used in a tubeless configuration, simplifying diabetes management with the benefits of Control-IQ+ technology. The full commercial launch of these new components is expected in the first half of 2027 in the U.S., with existing Tandem Mobi pumps being compatible.
Can Tandem Diabetes Care (TNDM) Stay Cheap After Its Recall?
Tandem Diabetes Care (TNDM) has seen an 87.2% share price decline over five years, with recent headlines focusing on a recall of 81,000 Mobi insulin pumps. Despite this, a Discounted Cash Flow (DCF) model suggests the company's intrinsic value is meaningfully above its current share price of $17.51, implying it may be undervalued. This analysis prompts a look into whether current valuation is supported by projected cash flows and what assumptions would justify its market price.
Is Tandem Diabetes Care (TNDM) Undervalued Following Its Mobi Pump Recall?
Tandem Diabetes Care (TNDM) is facing scrutiny after recalling approximately 81,000 Mobi insulin pumps due to false occlusion alarms, leading to a 22.9% share price drop over three months. Despite the recall, Simply Wall St's analyst consensus suggests TNDM is 36.9% undervalued, with a fair value of $27.76 compared to its current price of $17.51, emphasizing potential from improving margins and recurring revenue. However, the recall and infusion set constraints could impact future confidence and pump usage.
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
Tandem Diabetes Care has received Health Canada approval for several significant updates to its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology. These approvals include compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor and expanded indications for use in individuals with type 1 diabetes during pregnancy and adults with type 2 diabetes. These advancements are expected to be available in Canada in the second quarter of 2027, broadening access to innovative diabetes management technology.
Tandem Diabetes stock trades up, here is why
Shares of Tandem Diabetes Care jumped 10.4% after the company announced U.S. FDA clearance of its Tandem Mobi system, the first and only tubeless automated insulin delivery system wearable for up to seven days. This milestone is significant for addressing patient preferences and bolstering the company's competitive position. Despite recent volatility, the market reacted positively to the news, indicating potential new commercial growth opportunities upon the device's launch in the first half of 2027.
Earnings Update Might Change The Case For Investing In Tandem Diabetes Care (TNDM)
Tandem Diabetes Care (TNDM) reported third-quarter 2026 sales of US$283.69 million, a narrower net loss of US$7.09 million, and reaffirmed full-year revenue guidance. The company also appointed Jeannette Bankes as president, CEO, and director, bringing new leadership with deep industry experience. This update strengthens the investment narrative, as the company moves towards sustainable profitability despite ongoing risks like supply chain issues and product recalls.
Tandem Diabetes recalls about 81,000 Mobi insulin pumps over false occlusion alarms after 230 adverse events
Tandem Diabetes Care has recalled 80,938 Mobi insulin pumps due to false occlusion alarms that stop insulin delivery, a Class I recall by the FDA. The company has reported 230 adverse events requiring medical intervention or hospitalization, though no deaths. The issue stems from increased friction in the pump's drive module, which can falsely detect a blocked line, leading to high blood glucose if not addressed.
Tandem recalls Mobi insulin pump, reports 230 adverse events
Tandem Diabetes Care has issued a correction for over 80,000 Mobi insulin pumps due to a false occlusion alarm that can interrupt insulin delivery. The problem, caused by increased friction in the drive module, has led to 230 reported adverse events requiring medical intervention or hospitalization, though no deaths. Tandem advises users to respond to alarms, have a backup insulin delivery method, and contact customer support if alarms persist.
Tandem Diabetes Care, Inc. (TNDM) stock price, news, quote and history
Tandem Diabetes Care, Inc. (TNDM) stock closed at $17.51, down 6.71% on November 12th, 2026. The company, which specializes in technology solutions for diabetes management, has a market cap of $1.222 billion and reported a negative profit margin of -2.50% in Q3 FY26. Analysts currently have an average 1-year target estimate of $26.90 for the stock.
Goldman Sachs reports a passive stake above 5% in Tandem Diabetes Care (TNDM).
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC have reported a passive beneficial ownership stake of 5.9% in Tandem Diabetes Care, Inc. (TNDM) as of September 30, 2026. This stake consists of 4,091,935 shares, with both entities reporting shared voting and dispositive power over a significant portion of these shares. The filing, a Schedule 13G, indicates that the acquisition was made in the ordinary course of business and not for the purpose of influencing company control.
Tandem Diabetes names former GE HealthCare exec as president and CEO
Tandem Diabetes Care has appointed Jeannette Bankes as its new president and CEO, effective November 16, 2026. She will succeed John Sheridan, who is retiring at the end of 2026 after over a decade of service. Bankes brings more than 30 years of global operating experience, most recently serving as president and CEO of GE HealthCare’s Patient Care Solutions segment.
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
Tandem Diabetes Care (TNDM) reported a 14% revenue increase in Q3 2026, driven by higher pump shipments and international sales, though it signaled a slower-than-expected shift to pharmacy distribution could impact 2027 revenue growth. The company also announced CEO John Sheridan's retirement at year-end, with Jeannette Bankes taking over. Tandem reiterated its 2026 sales outlook and shared plans for new product launches, including the Mobi Tubeless system and a fully closed-loop system, pending FDA clearance and study completion.
Barclays maintains Tandem Diabetes Care at Equal-Weight, raises price target to $20 from $18
Barclays has reiterated its "Equal-Weight" rating for Tandem Diabetes Care (TNDM) and increased its price target to $20 from $18, representing an 11.1% hike. This new price target suggests an 11.2% upside from the stock's closing price of $17.99 on November 5. The article highlights that further details on price target data and analyst recommendations for Tandem Diabetes Care are available on the Forecasts tab and News Flow.
Tandem Diabetes Care names next CEO
Tandem Diabetes Care has announced Jeannette Bankes as its next CEO, effective November 16, succeeding John Sheridan who will retire at year-end. Bankes joins from GE HealthCare where she was CEO of patient care solutions. Sheridan, who led Tandem since 2019, will remain as a consultant after his retirement, having overseen the launch of key technologies like hybrid closed-loop systems and the development of a tubeless insulin pump.
Tandem Diabetes Care Inc (TNDM) Q3 2026 Earnings Call Highlights: Record Revenue and Pipeline ...
Tandem Diabetes Care Inc. reported record worldwide revenue of $284 million in Q3 2026, a 14% year-over-year increase, with pump shipments up 12%. The company saw improved gross margin and positive adjusted EBITDA, driven by strong international sales and new product launches. Despite these positives, pharmacy adoption is slower than expected, and supply shortages are impacting operations, leading to anticipated sales headwinds into 2027.
Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
Tandem Diabetes Care reported strong financial results for the third quarter of 2026, with worldwide sales increasing 14% to $283.7 million. The company expanded pharmacy formulary coverage to approximately 50% of U.S. lives and increased the availability of its t:slim X2 and Tandem Mobi insulin delivery systems internationally. Tandem Diabetes Care reaffirmed its full-year 2026 financial guidance, projecting sales between $1.065 billion and $1.085 billion.
Tandem Diabetes Care names successor as CEO Sheridan retires
Tandem Diabetes Care has announced Jeannette Bankes as its new president and CEO, succeeding John Sheridan, who will retire at the end of the year. Bankes, formerly of GE HealthCare and Boston Scientific, will assume her role on November 16th. Sheridan, who led Tandem since 2019, focused on advancing the company's Mobi insulin pump, expanding its international business, and initiating closed-loop device development before his retirement.
Tandem Diabetes Care Q3 2026 Earnings Call Transcript
Tandem Diabetes Care reported a 14% year-over-year revenue growth to $284 million in Q3 2026, with pump shipments up 12%. The company announced a planned CEO transition, with Jeanette Bankus set to succeed John Sheridan. Strategic priorities include expanding U.S. pharmacy sales, direct international operations, and advancing the Mobi Tubeless system, which is in late-stage FDA review.
Form 8K Tandem Diabetes Care Inc For: 5 November By Investing.com
This article announces that Tandem Diabetes Care Inc. filed a Form 8K on November 5. The article provides the title and date of the filing, along with the company's stock symbol TNDM. It reiterates the filing information multiple times.
Tandem Diabetes names Jeannette Bankes as new CEO
Tandem Diabetes Care (NASDAQ:TNDM) has appointed Jeannette Bankes as its new president and chief executive officer, effective November 16, 2026. Bankes will succeed John Sheridan, who is set to retire at the end of 2026 after over a decade with the company. Bankes brings over 30 years of healthcare industry experience from companies like GE HealthCare, Merck, Boston Scientific, and Alcon.
Tandem Diabetes Care Stock Faces Profit Strain and Debt Questions
Tandem Diabetes Care (NasdaqGM:TNDM) is facing significant financial pressure, marked by an 83.1% annual decline in EPS over five years despite revenue growth, negative returns on capital, and high net-debt-to-EBITDA. The company's investment narrative is challenged by these issues, raising concerns about its ability to fund future expansion without diluting shareholders. Analysts anticipate revenue growth and a swing to profit by 2029, with some estimates suggesting a 46% potential upside to its current stock price.
Tandem Diabetes (TNDM) reports earnings tomorrow: what to expect
Tandem Diabetes Care (NASDAQ: TNDM) is set to report earnings, with analysts expecting a 5.8% year-on-year revenue growth, an improvement from the 2.6% increase in the same quarter last year. The company previously met analysts' revenue expectations and its full-year revenue guidance, with EPS aligning with estimates. Investors have shown positive sentiment towards the healthcare technology sector, and Tandem Diabetes's stock is up 6.9% over the last month.
Technical Reactions to TNDM Trends in Macro Strategies
This article provides a technical analysis of Tandem Diabetes Care Inc. (NASDAQ: TNDM), indicating weak near-term sentiment but potential mid-term strength within a broader long-term weak bias. It highlights a significant 80.4:1 risk-reward setup targeting a 23.3% gain, and outlines three distinct AI-generated trading strategies: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, each with specific entry, target, and stop-loss zones.
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) announced that its management will present company updates at two upcoming investor conferences: the Jefferies Global Healthcare Conference on November 19, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 3, 2026. The presentations will be webcast live and archived on the company's Investor Center website. Tandem Diabetes Care is a leading insulin delivery and diabetes technology company based in San Diego, California.
Tandem Diabetes Care, Inc. (TNDM) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for Tandem Diabetes Care, Inc. (TNDM), displaying the average monthly price return between 2016 and 2026. It also provides real-time stock information, showing the current price, daily change, and after-hours trading activity for TNDM. The page includes standard financial data sections like news, charts, statistics, and historical data for the company.
Tandem Diabetes Care, Inc. (TNDM) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Tandem Diabetes Care, Inc. (TNDM), displaying average monthly price returns from 2016 to 2026. It shows the company's real-time price on NasdaqGM, along with its performance at close and after hours on October 30. The page also includes related tickers and various navigation options for financial data.
After exercising 1,700 options, a Tandem Diabetes Care (TNDM) director sold 1,700 shares at $19.15.
Tandem Diabetes Care Inc. director Christopher J. Twomey exercised 1,700 stock options at $19.00 per share on October 27, 2026, then immediately sold 1,700 common shares at $19.15 per share. This transaction was conducted under a Rule 10b5-1 trading plan. The report also detailed his indirect holdings through family investments and trusts.
Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tandem Diabetes Care, Inc. (TNDM) is expected to report a year-over-year increase in earnings and revenues for the quarter ended September 2026, with results anticipated on November 5. The company is projected to post a quarterly loss of $0.27 per share, an improvement of 12.9% year-over-year, on revenues of $265.29 million. While the Zacks Earnings ESP suggests a potential positive surprise for TNDM, its current Zacks Rank of #4 makes a definitive prediction difficult.
Tandem Diabetes Care (TNDM) Faces Execution Questions, Is The Stock Cheap Or Fairly Valued?
Tandem Diabetes Care (TNDM) shares have recently seen sharp swings but remain significantly undervalued according to a popular narrative, which suggests a fair value of $29.20 compared to the current price of $19.68. This implied upside relies on successful pharmacy channel expansion and sustained new pump starts, despite ongoing competitive pressures and execution risks. Investors are encouraged to review the underlying data to assess the company's future profitability and whether it aligns with their investment preferences.
Tandem Diabetes Care | 144: Notice of proposed sale of securities pursuant to Rule 144
This article is a notice of a proposed sale of securities by Tandem Diabetes Care, filed pursuant to Rule 144. It indicates a forthcoming transaction involving the company's stock.
Pharmacy Expansion Questions Put Tandem Diabetes Care Stock Execution In Focus
Tandem Diabetes Care's stock has recovered, but investors are now keenly focused on the company's execution regarding its pharmacy channel expansion and ability to monetize its installed insulin pump base. Analysts have differing views on the company's future revenue and earnings growth, with some predicting significant profit by 2029 while others remain bearish. The debate highlights the importance of operational execution, supply chain management, and competitive positioning for the company's long-term success.
Director Christopher Twomey proposes selling 1,700 Tandem Diabetes Care (TNDM) shares.
Tandem Diabetes Care director Christopher Twomey has filed a Form 144 to propose the sale of 1,700 common shares, acquired through the exercise of stock options, with an aggregate market value of $32,130.00. The transaction is set to occur on October 27, 2026, through Morgan Stanley Smith Barney LLC. This filing provides transparency regarding insider stock sales and the method of acquisition.
Tandem Diabetes Care, Inc. Estimates – NASDAQ:TNDM
This page provides an overview of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) financial estimates, allowing users to explore reported financial data and analyst estimates across various statements. It allows comparison of actual results with average, high, and low estimates, and visualization of trends over time for the income statement, balance sheet, and cash flow. The content explicitly states that it is not investment advice.
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $20
Citi has reiterated its Hold rating on Tandem Diabetes Care (TNDM.US) and maintained its target price at $20. This indicates a neutral outlook on the company's stock from the financial institution.
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts
This article provides a brief overview of Tandem Diabetes Care, Inc. (TNDM) based on an Argus report from October 14, 2026. Tandem Diabetes Care specializes in designing, manufacturing, and marketing durable insulin pumps, with its current flagship product being the t:slim X2 device. The report includes a current price of $16.52 for TNDM stock.
Form 4 Tandem Diabetes Care Inc: Jean-Claude Kyrillos (EVP & Chief Operating Officer) For: 15 October
This article reports on a Form 4 filing for Tandem Diabetes Care Inc., indicating an insider transaction involving Jean-Claude Kyrillos, the Executive Vice President and Chief Operating Officer. The filing pertains to activity on October 15th. The brief notice highlights a significant executive's transaction for the company.
Form 4 Tandem Diabetes Care Inc: Jean-Claude Kyrillos (EVP & Chief Operating Officer) For: 15 October
This article reports a Form 4 filing for Tandem Diabetes Care Inc, detailing a transaction involving Jean-Claude Kyrillos, the EVP & Chief Operating Officer. The filing is related to activity on October 15th. This is standard reporting for insider trading disclosures.
After a COO stock conversion, Tandem Diabetes Care (TNDM) withheld 1,926 shares for taxes; none were sold.
Tandem Diabetes Care's COO, Jean-Claude Kyrillos, converted 3,637 restricted stock units into common shares on October 15, 2026. The company withheld 1,926 shares for tax purposes at $16.52 per share, and no shares were sold by Kyrillos. His post-transaction RSU position is 10,908 shares.